IMMX | Immix Biopharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.6800 - 1.7950
52 Week Range	1.2600 - 3.13
Beta	0.98
Implied Volatility	292.55%
IV Rank	97.35%
Day's Volume	24,131
Average Volume	74,595
Shares Outstanding	27,722,109
Market Cap	47,127,585
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-12-16

Valuation
Profitability
Growth
Health
P/E Ratio	-2.24
Forward P/E Ratio	-3.05
EPS	-0.76
1YR Price Target	14.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	14
Country	USA
Website	IMMX

Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation.

IMMX's peers: ACHV, ALLR, ANNX, ATNF, AVIR, CELU, CNSP, DRMA, DRUG, GERN, ZVSA, HEPA, AVRO, EFTR, NAVB, SONN, FRLN, ENVB, CWBR, ELEV, OCEA, IMRN, INM, CYBN, LEXX, NBTX, NBY, ORMP, PALI, PHAT, PHGE, PHIO, PSTV, QLGN, RCUS, RIGL, RNAZ, RXRX, SLS, SNGX, VTVT, XBIO, CDIO, ERNA, ICU, SPRY, CMND, CARM

*Chart delayed

Analyzing fundamentals for IMMX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see IMMX Fundamentals page.

Watching at IMMX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IMMX Technicals page.